Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

Company Reiterates 2008 Earnings Guidance and Introduces Q1 2008 Guidance

FRAZER, Pa., Feb. 12 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported 2007 sales of $1.727 billion, compared to sales of $1.720 billion for 2006, exceeding the company's previously issued guidance. Basic loss per common share for the full year 2007 was $2.88. Excluding the previously announced settlement reserve, amortization expense and certain other items, basic adjusted income per common share for the full year was $4.64, which compares to $5.22 for 2006 and exceeds the high end of the company's earnings guidance range of $4.45 to $4.55.

2007 central nervous system (CNS) franchise sales increased 16 percent to $909.4 million compared to 2006 and the pain franchise reported strong sales of $512.6 million, a decrease of only 22 percent despite a full year of generic competition to ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. Sales of other products increased 15 percent to $305.3 million.

"We delivered strong performance across all aspects of our business in 2007. We launched AMRIX, filed three NDAs, introduced three new Phase 1 programs, and delivered greater sales and earnings than expected," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "We believe that 2008 will mark the beginning of a new phase of growth for the company with a full year of AMRIX sales, the potential for approval of TREANDA and expanded indications for FENTORA, and continued progress on the clinical development plan for NUVIGIL. In fact, the NUVIGIL program is already off to a great start with promising results from our first Phase 2 study in the treatment of schizophrenia."

The company is reiterating its guidance for 2008 total sales of $1.80 - $1.85 billion, adjusted net income of $344 - $351 million and its basic adjusted income per common share guidance of $5.10 - $5.20.

Cephalon is introducing first quarter 2008 sales guidance of $435 - $445 milling, general and administrative expenses and $11.7 million in

Income tax expense related to SFAS 123(R).

CEPHALON, INC. AND SUBSIDIARIES

"ADJUSTED" CONSOLIDATED SALES DETAIL *

(In thousands)

(Unaudited)

Three Months Ended

December 31,

2007

United

States Europe Total

Sales:

PROVIGIL $208,245 $11,237 $219,482

GABITRIL 10,828 400 11,228

CNS 219,073 11,637 230,710

ACTIQ 42,310 12,027 54,337

Generic OTFC 31,471 - 31,471

FENTORA 33,912 - 33,912

AMRIX 8,401 - 8,401

Pain 116,094 12,027 128,121

Other 15,396 65,270 80,666

$350,563 $88,934 $439,497

Three Months Ended

December 31,

2006

United

States Europe Total

Sales:

PROVIGIL $190,838 $13,833 $204,671

GABITRIL 12,805 806 13,611

CNS 203,643 14,639 218,282

ACTIQ 100,882 8,039 108,921

Generic OTFC 46,630 - 46,630

FENTORA 29,250 - 29,250

AMRIX - - -

Pain 176,762 8,039 184,801

Other 14,423 55,841 70,264

$394,828 $78,519 $473,347

%

Increase

(Decrease)

United

States Europe Total

Sales:

PROVIGIL 9% (19%) 7%

GABITRIL (15%) (50%) (18%)

CNS 8% (21%) 6%

ACTIQ (58%) 50% (50%)

Generic OTFC (33%) 0% (33%)

FENTORA 16% 0% 16%

AMRIX 100% 0% 100%

Pain (34%) 50% (31%)

Other 7% 17% 15%

(11%) 13% (7%)

Year Ended

December 31,

2007

United

States Europe Total

Sales:

PROVIGIL $801,639 $50,408 $852,047

GABITRIL 50,642 6,668 57,310

CNS 852,281 57,076 909,357

ACTIQ 199,407 40,665 240,072

Generic OTFC 129,033 - 129,033

FENTORA 135,136 - 135,136

AMRIX 8,401 - 8,401

Pain 471,977 40,665 512,642

Other 69,263 236,037 305,300

$1,393,521 $333,778 $1,727,299

Year Ended

December 31,

2006

United

States Europe Total

Sales:

PROVIGIL $684,885 $43,052 $727,937

GABITRIL 54,096 4,316 58,412

CNS 738,981 47,368 786,349

ACTIQ 544,886 27,252 572,138

Generic OTFC 54,801 - 54,801

FENTORA 29,250 - 29,250

AMRIX - - -

Pain 628,937 27,252 656,189

Other 56,084 208,277 264,361

$1,424,002 $282,897 $1,706,899

%

Increase

(Decrease)

United

States Europe Total

Sales:

PROVIGIL 17% 17% 17%

GABITRIL (6%) 54% (2%)

CNS 15% 20% 16%

ACTIQ (63%) 49% (58%)

Generic OTFC 135% 0% 135%

FENTORA 362% 0% 362%

AMRIX 100% 0% 100%

Pain (25%) 49% (22%)

Other 23% 13% 15%

(2%) 18% 1%

* For the year ended December 31, 2006, amounts exclude the impact of the

DoD Tricare program reversal of $13.3 million which reduced GAAP U.S.

sales of PROVIGIL, GABITRIL and ACTIQ by $6.9 million, $0.9 million and

$5.5 million, respectively.

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

December 31, December 31,

2007 2006

CURRENT ASSETS:

Cash and cash equivalents $818,669 $496,512

Investments 7,596 25,212

Receivables, net 276,776 270,045

Inventory, net 99,098 85,239

Deferred tax assets, net 176,619 184,518

Other current assets 43,267 47,278

Total current assets 1,422,025 1,108,804

PROPERTY AND EQUIPMENT, net 500,396 453,010

GOODWILL 476,515 467,167

INTANGIBLE ASSETS, net 817,828 793,037

DEFERRED TAX ASSETS, net 160,134 118,192

OTHER ASSETS 129,371 105,287

$3,506,269 $3,045,497

CURRENT LIABILITIES:

Current portion of long-term debt $1,237,169 $1,023,312

Accounts payable 91,437 90,586

Accrued expenses 677,184 263,478

Total current liabilities 2,005,790 1,377,376

LONG-TERM DEBT 3,788 224,992

DEFERRED TAX LIABILITIES, net 56,540 72,491

OTHER LIABILITIES 138,084 61,178

Total liabilities 2,204,202 1,736,037

STOCKHOLDERS' EQUITY:

Common stock, $0.01 par value 700 678

Additional paid-in capital 1,934,965 1,780,749

Treasury stock, at cost (158,173) (151,068)

Accumulated deficit (624,128) (425,256)

Accumulated other comprehensive income 148,703 104,357

Total stockholders' equity 1,302,067 1,309,460

$3,506,269 $3,045,497

Certain reclassifications of prior year amounts have been made to conform

to the current year presentation. The NUVIGIL(R) (armodafinil) [C-IV]

inventory balance of $89.1 million as of December 31, 2006 has been

reclassified from inventory to other assets, as we do not presently intend

to launch NUVIGIL commercially until around 2010.

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Year Ended

December 31,

2007 2006

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income (loss) $(191,704) $144,816

Adjustments to reconcile net

income (loss) to net cash

provided by operating activities:

Deferred income tax

expense (benefit) (958) 28,064

Shortfall tax benefits from

stock-based compensation (360) -

Debt exchange expense - 48,122

Depreciation and amortization 141,358 126,531

Amortization of debt issuance

costs 241 493

Write-off of debt issuance costs

associated with convertible

subordinated notes - 13,105

Stock-based compensation expense 46,695 42,807

Gain on extinguishment of debt (5,319) -

Gain on sale of investment (5,791) -

Loss on disposals of property and

equipment 3,346 3,292

Impairment charge - 12,417

Changes in operating assets and

liabilities:

Receivables (601) (63,932)

Inventory (6,023) 22,640

Other assets (54,967) (7,033)

Accounts payable and

accrued expenses 382,898 (19,764)

Other liabilities 76,041 (31,641)

Net cash provided by

operating activities 384,856 319,917

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and equipment (96,867) (159,917)

Acquisition of intangible assets (107,246) (115,850)

Proceeds from sale of investment 12,291 -

Sales and (purchases) of

available-for-sale investments, net 18,876 255,391

Net cash used for

investing activities (172,946) (20,376)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from exercises of common

stock options 93,900 143,491

Windfall tax benefits from stock-based

compensation 13,993 27,189

Acquisition of treasury stock (7,105) (4,418)

Payments on and retirements of long-term

debt (3,853) (188,886)

Net cash provided by (used for)

financing activities 96,935 (22,624)

EFFECT OF EXCHANGE RATE CHANGES ON

CASH AND CASH EQUIVALENTS 13,312 14,535

NET INCREASE IN CASH AND CASH EQUIVALENTS 322,157 291,452

CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 496,512 205,060

CASH AND CASH EQUIVALENTS, END OF YEAR $818,669 $496,512

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of Projected GAAP Basic Income per Common Share

to Basic Adjusted Income Per Common Share Guidance

(Unaudited)

Three Months Twelve Months

Ended Ended

March 31, 2008 December 31, 2008

Projected GAAP basic income per common

share $0.74 - $0.84 $4.04 - $4.14

Amortization of current intangibles $0.42 - $0.42 $1.68 - $1.68

Tax effect of pre-tax adjustments at

the applicable tax rates $(0.16)- $(0.16) $(0.62)- $(0.62)

Basic adjusted income per common share

guidance $1.00 - $1.10 $5.10 - $5.20

The company's guidance is being issued based on certain assumptions

including:

-- Entrance into the market of an additional generic version of ACTIQ by

mid-2008;

-- Approval of TREANDA and mid-2008 launch;

-- Reduction of interest income by $20 million resulting from payment of

the settlement with the U.S. Attorney's Office;

-- Adjusted effective tax rate of approximately 36 to 37 percent; and

-- Weighted average number of common shares outstanding of 67.5 million

shares for the three months ended March 31, 2008 and for the twelve

months ended December 31, 2008, respectively.

lion, adjusted net income guidance of $67.7 - $74.5 million and basic adjusted income per common share guidance of $1.00 - $1.10.

Basic adjusted income per common share guidance for both the first quarter 2008 and full-year 2008 is reconciled below and is subject to the assumptions set forth therein.

Cephalon's management will discuss the company's fourth quarter and full year 2007 performance in a conference call with investors beginning at 5:00 p.m. U.S. EST on Tuesday, February 12, 2008. To participate in the conference call, dial +1-913-312-0669 and refer to conference code number 4647168. Investors can listen to the call live by logging on to the company's website at http://www.cephalon.com and clicking on "Investor Information," then "Webcast." The conference call will be archived and available to investors for one week after the call.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs close to 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide), AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), and ACTIQ(R). The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products including NUVIGIL for the treatment of schizophrenia; interpretation of clinical results; prospects for regulatory approval, including with respect to TREANDA and NUVIGIL; manufacturing development and capabilities; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance for the first quarter and full-year 2008; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward- looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

This press release and/or the financial results attached to this press release include "Adjusted Net Income," "Basic Adjusted Income per Common Share," "Adjusted Net Income Guidance, "Basic Adjusted Income per Common Share Guidance," and "Diluted Adjusted Income Per Common Share," amounts that are considered "non-GAAP financial measures" under SEC rules. As required, we have provided reconciliations of these measures. Additional required information is located in the Form 8-K furnished to the SEC in connection with this press release.

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

REVENUES:

Sales $439,497 $473,347 $1,727,299 $1,720,172

Other revenues 10,474 11,335 45,339 43,897

449,971 484,682 1,772,638 1,764,069

COSTS AND EXPENSES:

Cost of sales 89,897 88,171 341,867 338,784

Research and development 95,037 129,340 369,115 424,239

Selling, general and

administrative 207,837 219,334 735,799 689,492

Settlement reserve - - 425,000 -

Impairment charge - - - 12,417

Acquired in-process research

and development - 5,000 - 5,000

392,771 441,845 1,871,781 1,469,932

INCOME (LOSS) FROM OPERATIONS 57,200 42,837 (99,143) 294,137

OTHER INCOME (EXPENSE):

Interest income 9,331 8,702 32,816 25,438

Interest expense (4,561) (5,399) (19,833) (18,922)

Debt exchange expense - (48,122) - (48,122)

Write-off of deferred debt

issuance costs - - - (13,105)

Gain on extinguishment of debt - - 5,319 -

Gain on sale of investment - - 5,791 -

Other income (expense), net 2,884 (1,056) 6,631 (1,172)

7,654 (45,875) 30,724 (55,883)

INCOME (LOSS) BEFORE INCOME

TAXES 64,854 (3,038) (68,419) 238,254

INCOME TAX EXPENSE 20,672 1,871 123,285 93,438

NET INCOME (LOSS) $44,182 $(4,909) $(191,704) $144,816

BASIC INCOME (LOSS) PER COMMON

SHARE $0.66 $(0.08) $(2.88) $2.39

DILUTED INCOME (LOSS) PER

COMMON SHARE $0.56 $(0.08) $(2.88) $2.08

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING 67,187 61,783 66,597 60,507

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING-

ASSUMING DILUTION 78,734 61,783 66,597 69,672

Certain reclassifications of prior year amounts have been made to conform

to the current year presentation. Amounts reported in prior periods as

amortization are included now as a component of cost of sales; amounts

previously reported as depreciation (other than depreciation related to

facilities used in the production of commercial inventory and previously

included in cost of sales) are included as a component of research and

development or selling, general and administrative, as appropriate.

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income

(Unaudited)

Three Months Ended

December 31,

2007 2006

GAAP NET INCOME (LOSS) $44,182 $(4,909)

Cost of sales adjustments 26,306 (1) 20,958 (1)

Research and development adjustments 2,000 (2) 35,500 (2) (7)

Selling, general and administrative

adjustments 11,191 (3) - (7)

Acquired in-process research and

development - 5,000 (5)

Debt exchange expense - 48,122 (6)

Income taxes (18,149)(4) (30,831)(4) (7)

21,348 78,749

ADJUSTED NET INCOME $65,530 $73,840

BASIC ADJUSTED INCOME PER COMMON SHARE $0.98 $1.20

DILUTED ADJUSTED INCOME PER COMMON

SHARE $0.83 $1.00

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 67,187 61,783

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 78,734 73,633 Notes to Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets.

(2) To exclude charges related to payments for several research and

development collaborations.

(3) To exclude charges related to certain employee severance costs ($7.2

million) and a significant one-time charitable contribution ($4.0

million).

(4) To reflect the tax effect of pre-tax adjustments at the applicable tax

rates and certain other tax adjustments primarily related to changes

in valuation allowances and other changes in tax assets and

liabilities.

(5) To exclude the write-off of other acquired in-process research and

development.

(6) To exclude the debt exchange expense associated with the December 2006

exchanges of $337.0 million of zero coupon convertible subordinated

notes and $100.0 million of 2% senior subordinated convertible notes.

(7) Amounts shown no longer exclude the impact of Financial Accounting

Standards Board Statement No. 123(R) "Share Based Payment" ("SFAS

123(R)"). The earnings press release issued on February 12, 2007

reflected adjustments of $3.7 million in each of Research and

development and Selling, general and administrative expenses and $2.9

million in Income tax expense related to SFAS 123(R).

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income

(Unaudited)

Year Ended

December 31,

2007 2006

GAAP NET INCOME (LOSS) $(191,704) $144,816

Sales adjustments - (13,273)(8)

Cost of sales adjustments 90,542 (1) 90,333 (1)

Research and development adjustments 43,500 (2) 80,500 (2) (13)

Selling, general and administrative

adjustments 11,191 (3) 9,987 (3) (13)

Settlement reserve 425,000 (4) -

Impairment charge - 12,417 (9)

Acquired in-process research and

development - 5,000 (10)

Debt exchange expense - 48,122 (11)

Write-off of deferred debt issuance

costs - 13,105 (12)

Gain on extinguishment of debt (5,319)(5) -

Gain on sale of investment (5,791)(6) -

Income taxes (58,608)(7) (74,891)(7) (13)

500,515 171,300

ADJUSTED NET INCOME $308,811 $316,116

BASIC ADJUSTED INCOME PER COMMON SHARE $4.64 $5.22

DILUTED ADJUSTED INCOME PER COMMON

SHARE $3.92 $4.54

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 66,597 60,507

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 78,684 69,672 Notes to Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income

(1) In 2007, to exclude the on-going amortization of acquired intangible

assets. In 2006, to exclude the reserve for SPARLON capitalized

inventory costs ($8.6 million) and the on-going amortization of

acquired intangible assets ($81.7 million).

(2) In 2007, to exclude charges related to payments for several research

and development collaborations ($28.5 million) and the recognition of

a milestone related to the FDA's acceptance of our NDA filing for

TREANDA(R) (bendamustine HCl) ($15.0 million). In 2006, to exclude

charges related to payments for several research and development

collaborations.

(3) In 2007, to exclude charges related to certain employee severance

costs ($7.2 million) and a significant one-time charitable

contribution ($4.0 million). In 2006, to exclude charges associated

with the settlement of the PROVIGIL patent litigation ($6.0 million)

and employee severance costs associated with the European integration

and restructuring ($4.0 million).

(4) To exclude the reserve established for the agreement in principle

reached with the U.S. Attorney's Office in Philadelphia.

(5) To exclude the forgiveness of a mortgage loan by the Pennsylvania

Industrial Development Board.

(6) To exclude the pre-tax gain related to the sale of certain

investments.

(7) To reflect the tax effect of pre-tax adjustments at the applicable tax

rates and certain other tax adjustments primarily related to changes

in valuation allowances and other changes in tax assets and

liabilities.

(8) To exclude the U.S. Department of Defense ("DoD") Tricare program

reversal as a result of the U.S. Court of Appeals September 2006

ruling.

(9) To exclude charges related to the impairment of an intangible asset.

(10) To exclude the write-off of other acquired in-process research and

development.

(11) To exclude the debt exchange expense associated with the December

2006 exchanges of $337.0 million of zero coupon convertible

subordinated notes and $100.0 million of 2% senior subordinated

convertible notes.

(12) To exclude the write-off of deferred debt issuance costs related to

the Zero Coupon convertible subordinated notes.

(13) Amounts shown no longer exclude the impact of SFAS 123(R). The

earnings press release issued on February 12, 2007 reflected

adjustments of $15.3 million in each of Research and development and

Sel
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC reports the ... Sonalink™ remote monitoring. The inaugural launch of this new technology occurred over the ... Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. , ...
(Date:2/10/2016)... Miami, FL (PRWEB) , ... February 10, 2016 ... ... leader in regenerative medicine, has announced a new agreement with Singapore-based Global Stem ... qualified physicians from the Philippines, Thailand and Singapore in the latest adipose and ...
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November and the ... will bring together over 500 top healthcare leaders for a night and day of ... organized by MBA students of the University of Pennsylvania’s Wharton School, will be held ...
(Date:2/9/2016)... ... 08, 2016 , ... Net-Translators, an industry-leading provider of translation, ... revamped and improved website. In an on-going effort to further educate customers and ... communicate how the company designs and delivers thorough, high-quality results for its growing ...
Breaking Biology Technology:
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... 2016  Based on its recent analysis of ... US-based Intelligent Retinal Imaging Systems (IRIS) with the ... New Product Innovation. IRIS, a prominent cloud-based retinal ... , is poised to set the new ... market. The IRIS technology presents superior price-performance value ...
Breaking Biology News(10 mins):